Cleared Traditional

K073390 - DIASORIN LIASON RUBELLA IGG ASSAY (FDA 510(k) Clearance)

Also includes:
DIASORIN LIAISON RUBELLA IGG TRI-CONTROLS
Nov 2008
Decision
354d
Days
Class 2
Risk

K073390 is an FDA 510(k) clearance for the DIASORIN LIASON RUBELLA IGG ASSAY. This device is classified as a Enzyme Linked Immunoabsorbent Assay, Rubella (Class II - Special Controls, product code LFX).

Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on November 21, 2008, 354 days after receiving the submission on December 3, 2007.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3510.

Submission Details

510(k) Number K073390 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 03, 2007
Decision Date November 21, 2008
Days to Decision 354 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LFX — Enzyme Linked Immunoabsorbent Assay, Rubella
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3510